Skip to main content
. 2021 Sep 1;10(4):2525–2538. doi: 10.1007/s40121-021-00524-5

Fig. 3.

Fig. 3

Antifungal therapy for IPA: a distribution of antifungal drugs prescribed in ACLF patients with probable IPA; b loading doses and c maintenance doses of voriconazole in ACLF patients; d cumulative 28-day mortality of patients treated with voriconazole therapy and non-voriconazole therapy (66.6% vs. 38.3%, p = 0.001). Log-rank test was performed; e trough voriconazole concentrations comparing patients treated with an optimal voriconazole regimen and those with other voriconazole regimens within 30 days